Cancer detection and classification using methylome analysis
There is described herein a method of detecting the presence of DNA from cancer cells in a subject comprising: providing a sample of cell-free DNA from a subject; subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated, then optionally denaturing the sample; capturing cell-free methylated DNA using a binder selective for methylated polynucleotides; sequencing the captured cell-free methylated DNA; comparing the sequences of the captured cell-free methylated DNA to control cell-free methylated DNAs sequences from healthy and cancerous individuals and from individuals with distinct cancer types and subtypes; identifying the presence of DNA from cancer cells if there is a statistically significant similarity between one or more sequences of the captured cell-free methylated DNA and cell-free methylated DNAs sequences from cancerous individuals.
1. A method comprising:
(a) providing a sample of cell-free DNA from a subject;
(b) adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated, and wherein the first amount of filler DNA is from about 20 nanograms (ng) to about 100 ng;
(c) capturing cell-free methylated DNA using a binder selective for methylated polynucleotides;
(d) sequencing the captured cell-free methylated DNA to generate a plurality of sequencing reads; and
(e) computer processing the plurality of sequencing reads to obtain a methylation profile of the subject.
2. The method of claim 1 , wherein the sample is from the subject's blood or plasma.
3. The method of claim 1 , further comprising: (f) processing the methylation profile of the subject to a reference methylation profile using a machine-learning derived classifier.
4. The method of claim 3 , wherein the classifier is an elastic net classifier, lasso, support vector machine, random forest, or neural network.
5. The method of claim 3 , wherein the reference methylation profile is derived from a database of Differentially Methylated Regions (DMRs) between healthy and cancerous individuals.
6. The method of claim 3 , wherein the reference methylation profile is limited to those regions which are differentially methylated as between healthy and cancerous individuals in DNA derived from cell-free DNA.
7. The method of claim 3 , wherein the reference methylation profile is limited to those regions which are differentially methylated as between healthy and cancerous individuals in DNA derived from blood plasma.
8. The method of claim 1 , wherein the sample has less than 100 ng, 75 ng, or 50 ng of cell-free DNA.
9. The method of claim 1 , wherein the first amount of filler DNA comprises between about 5% and about 50% methylated filler DNA.
10. The method of claim 1 , wherein the first amount of filler DNA is from about 30 ng to about 100 ng.
11. The method of claim 1 , wherein step (c) comprises immunoprecipitating the cell-free methylated DNA using an antibody.
12. The method of claim 1 , further comprising, prior to step (c), adding a second amount of control DNA to the sample for confirming the capturing of the cell-free methylated DNA.
13. The method of claim 1 , further comprising identifying a presence of DNA from cancer cells, and identifying cancer cell tissue of origin.
14. The method of claim 13 , wherein identifying the cancer cell tissue of origin further includes identifying a cancer subtype.
15. The method of claim 14 , wherein the cancer subtype differentiates the cancer based on stage, histology, gene expression pattern, copy number aberration, rearrangement, or point mutational status.
16. The method of claim 1 , wherein the computer processing in step (e) is carried out genome-wide.
17. The method of claim 1 , wherein the computer processing in step (e) is restricted to specific regulatory regions.
18. The method of claim 17 , wherein the regulatory regions are FANTOM5 enhancers, CpG Islands, CpG shores, CpG Shelves, or any combination of the foregoing.
19. The method of claim 1 , wherein the first amount of filler DNA comprises at least 10% methylated filler DNA.
20. The method of claim 1 , wherein the first amount of filler DNA comprises between about 15% to about 30% methylated filler DNA.
21. The method of claim 1 , wherein the first amount of filler DNA is from about 50 ng to about 100 ng.
22. A method for identifying a cancer subtype in a subject, the method comprising:
(a) adding a first amount of filler DNA to a sample of cell-free DNA obtained from the subject, wherein at least a portion of the filler DNA is methylated, and wherein the first amount of filler DNA is from about 20 nanograms (ng) to about 100 ng;
(b) capturing cell-free methylated DNA using a binder selective for methylated polynucleotides and sequencing the captured cell-free methylated DNA to generate a plurality of sequencing reads;
(c) computer processing the plurality of sequencing reads to obtain a methylated profile of the subject; and
(d) computer processing the methylation profile with a reference methylation profile to identify a cancer subtype and cancer cell tissue of origin in the subject.